![[18F]-FPBM2 : SERT(5HTT) imaging agents](https://impro.usercontent.one/appid/oneComWsb/domain/zhulinbnu.com/media/zhulinbnu.com/onewebmedia/Screen%20Shot%202025-01-10%20at%2012.43.57%20PM.png?etag=%226e86b-67815c73%22&sourceContentType=image%2Fpng&ignoreAspectRatio&resize=1000,339&quality=85 "[18F]-FPBM2 : SERT(5HTT) imaging agents")
[18F]-FPBM2 : SERT(5HTT) imaging agents
![[18F]-FPBM2 & FPBM : SERT(5HTT) imaging agents](https://impro.usercontent.one/appid/oneComWsb/domain/zhulinbnu.com/media/zhulinbnu.com/onewebmedia/i285134164475700322.jpg?etag=%221b68c-5db44839af051%22&sourceContentType=&ignoreAspectRatio&resize=1000,334 "[18F]-FPBM2 & FPBM : SERT(5HTT) imaging agents")
[18F]-FPBM2 & FPBM : SERT(5HTT) imaging agents
Key Features of [18F]-FPBM2
- High Selectivity for SERT – Demonstrates strong affinity and specificity for serotonin transporters, minimizing off-target binding.
- Fluorine-18 Labeling – Enables high-resolution PET imaging with optimal half-life (~110 min) for clinical and research use.
- Potential for Clinical Application – Useful for studying psychiatric disorders (e.g., major depressive disorder, anxiety disorders) and neurodegenerative diseases (e.g., Parkinson’s disease, Alzheimer’s disease).
Applications in Neuroimaging
- Depression and Mood Disorders – Imaging studies with [18F]-FPBM2 may help assess SERT density alterations in patients with depression and evaluate treatment response to selective serotonin reuptake inhibitors (SSRIs).
- Neurodegenerative Diseases – SERT dysfunction has been linked to Parkinson’s and Alzheimer’s disease, making [18F]-FPBM2 a valuable tool for studying disease progression and potential therapeutic interventions.
- Drug Development & Pharmacokinetics – Can be used in translational research to evaluate new SERT-targeted therapies and monitor drug occupancy at serotonin transporters.
[18F]-FPBM2 & FPBM : SERT(5HTT) imaging agents
Publications:
1.Liu, F, et al. "Deuterium‐substituted 2‐(2′‐((dimethylamino) methyl)‐4′‐[18F](fluoropropoxy) phenylthio) benzenamine as a serotonin transporter imaging agent." Journal of Labelled Compounds and Radiopharmaceuticals 61.8 (2018): 576-585.
2.Zhang, Y., et al. "Fluorine-18 labeled diphenyl sulfide derivatives for imaging serotonin transporter (SERT) in the brain." Nuclear medicine and biology 66 (2018): 1-9.
3.Sun, M., et al. "Rapid screening of nine unradiolabeled candidate compounds as PET brain imaging agents using cassette-wave microdosing and LC-MS/MS." Journal of Chromatography B 1121 (2019): 28-38.
4.Zhu, L., et al. "An improved preparation of [18F] FPBM: a potential serotonin transporter (SERT) imaging agent." Nuclear medicine and biology 40.8 (2013): 974-979.
5.Qiao, H., et al. "One-step preparation of [18F] FPBM for PET imaging of serotonin transporter (SERT) in the brain." Nuclear medicine and biology 43.8 (2016): 470-477.
6.Xiao, H., et al. "Developing a cassette microdosing approach to enhance the throughput of PET imaging agent screening." Journal of pharmaceutical and biomedical analysis 154 (2018): 48-56.
7.Wang, JL., et al. "In vivo studies of the SERT-selective [18F] FPBM and VMAT2-selective [18F] AV-133 radiotracers in a rat model of Parkinson's disease." Nuclear medicine and biology 37.4 (2010): 479-486.
